Brief: Valneva H1 Revenue EUR 65.8 Million
13/08/2026 06:02
BRIEF-Valneva H1 Revenue EUR 65.8 Million Aug 13 (Reuters) - Valneva SE VLS.PA:
VALNEVA H1 REVENUE EUR 65.8 MILLION
VALNEVA H1 NET INCOME EUR -63.3 MILLION
VALNEVA H1 ADJUSTED EBITDA EUR -40.1 MILLION
CASH POSITION WAS EUR 121.5 MILLION AS OF JUNE 30, 2026
REAFFIRMED ITS 2026 GUIDANCE
REGULATORY DECISIONS FOR LYME DISEASE VACCINE CANDIDATE EXPECTED IN NEXT TWELVE MONTHS
PRODUCT GROSS MARGINS ARE EXPECTED TO IMPROVE IN H2
AGREED TO SELL ITS NANTES SITE IN FRANCE FOR EUR 6.2 MILLION
NANTES SITE: PRELIMINARY SALE AGREEMENT SIGNED WITH NANTES MÉTROPOLE; TRANSACTION IS EXPECTED TO CLOSE IN SEPT 2026
Source text: ID:nGNE2tdVFG
Further company coverage: VLS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency